Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 3/2019

01-06-2019 | Breast Cancer | Research Article

Quantitative Imaging of Morphometric and Metabolic Signatures Reveals Heterogeneity in Drug Response of Three-Dimensional Mammary Tumor Spheroids

Author: V. Krishnan Ramanujan

Published in: Molecular Imaging and Biology | Issue 3/2019

Login to get access

Abstract

Purpose

In order to monitor the drug responses of three-dimensional mammary tumor spheroids and to elucidate the role of inter- and intra-spheroid heterogeneity in determining drug sensitivity in the spheroids, an integrated image analysis framework was developed for morphometric and metabolic characterization of the three-dimensional tumor spheroids.

Procedure

Three-dimensional spheroid cultures of primary mammary tumor epithelial cells isolated from freshly excised tumors from a transgenic mouse model of adenocarcinoma (MMTV-PyMT) were imaged by using vital dyes and mitochondrial membrane potential markers. Custom-developed java and python program codes facilitated image processing, numerical computation, and graphical analysis of large datasets generated from the experiments. A panel of cancer drugs (rapamycin, BEZ235, MK2206, and flavopiridol) was tested to determine the degree of drug sensitivity as well as heterogeneity in drug response.

Results

A new quantitative metric (growth/toxicity) was developed based on morphometric parameters that were found to track the growth and apoptotic cell populations. Further, this study identified two parameters, namely, skew and kurtosis—which report the spatial heterogeneity in mitochondrial metabolism within the spheroids. The results of this study show that three-dimensional tumor spheroids selectively respond to cancer drugs depending on the specific metabolic pathways (AKT inhibition pathway in the present study), and there exists significant heterogeneity in the untreated tumor spheroids. Drug sensitivity of the spheroids was found to be associated with significant alterations in mitochondrial heterogeneity within the spheroids.

Conclusions

In conclusion, the quantitative imaging of morphometric and metabolic analysis in large image datasets can serve as an excellent tool box for characterizing tumor heterogeneity in three-dimensional tumor spheroids and potentially, in intact tumors as well.
Appendix
Available only for authorised users
Literature
1.
2.
Tennant DA, Duran RV, Boulahbel H, Gottlieb E (2009) Metabolic transformation in cancer. Carcinogenesis 30:1269–1280CrossRefPubMed
3.
Narod S (2016) Breast cancer: the importance of overdiagnosis in breast-cancer screening. Nat Rev Clin Oncol 13:5–6CrossRefPubMed
4.
5.
Potts SJ, Krueger JS, Landis ND, Eberhard DA, David Young G, Schmechel SC, Lange H (2012) Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Lab Investig 92:1342–1357CrossRefPubMed
6.
7.
Kim JB, O'Hare MJ, Stein R (2004) Models of breast cancer: is merging human and animal models the future? Breast Cancer Res 6:22–30CrossRefPubMed
8.
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7:96CrossRefPubMedPubMedCentral
9.
10.
Ma Z, Shiao SL, Yoshida EJ, Swartwood S, Huang F, Doche ME, Chung AP, Knudsen BS, Gertych A (2017) Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate. Diagn Pathol 12:69CrossRefPubMedPubMedCentral
11.
12.
Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4:309–324CrossRefPubMed
13.
Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113–2126CrossRefPubMedPubMedCentral
14.
Ramanujan VK (2019) Rapid assessment of mitochondrial complex I activity and metabolic phenotyping of breast cancer cells by NAD(p)H cytometry. Cytometry Part A 95:101–109
15.
16.
Najafi M, Soltanian-Zadeh H, Jafari-Khouzani K, Scarpace L, Mikkelsen T (2012) Prediction of Glioblastoma Multiform Response to Bevacizumab Treatment Using Multi-Parametric MRI. PLoS One 7:e29945CrossRefPubMedPubMedCentral
17.
Stottrup C, Tsang T, Chin YR (2016) Upregulation of AKT3 confers resistance to the AKT inhibitor MK2206 in breast Cancer. Mol Cancer Ther 15:1964–1974CrossRefPubMedPubMedCentral
18.
Wang H, Huang F, Wang J, Wang P, Lv W, Hong L, Li S, Zhou J (2015) The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206. Cell Cycle 14:232–242CrossRefPubMedPubMedCentral
19.
Tan AR, Swain SM (2002) Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol 29:77–85CrossRefPubMed
20.
21.
Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL (2018) Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer consortium trial. In: Clin Transl Oncol, vol 20, pp 1474–1483
22.
Blagosklonny MV (2004) Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 3:1537–1542CrossRefPubMed
23.
Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, Burma S (2012) The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14:34–43CrossRefPubMedPubMedCentral
24.
Trilla-Fuertes L, Gamez-Pozo A, Arevalillo JM et al (2018) Molecular characterization of breast cancer cell response to metabolic drugs. Oncotarget 9:9645–9660CrossRefPubMedPubMedCentral
25.
Xu HN, Zheng G, Tchou J, Nioka S, Li LZ (2013) Characterizing the metabolic heterogeneity in human breast cancer xenografts by 3D high resolution fluorescence imaging. Springerplus 2:73CrossRefPubMedPubMedCentral
26.
Bellance N, Lestienne P, Rossignol R (2009) Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 14:4015–4034
27.
28.
Collins TJ, Bootman MD (2003) Mitochondria are morphologically heterogeneous within cells. J Exp Biol 206:1993–2000CrossRefPubMed
29.
Ye XQ, Wang GH, Huang GJ, Bian XW, Qian GS, Yu SC (2011) Heterogeneity of mitochondrial membrane potential: a novel tool to isolate and identify cancer stem cells from a tumor mass? Stem Cell Rev 7:153–160CrossRef
30.
Kuznetsov AV, Margreiter R (2009) Heterogeneity of mitochondria and mitochondrial function within cells as another level of mitochondrial complexity. Int J Mol Sci 10:1911–1929CrossRefPubMedPubMedCentral
31.
Rohwer N, Cramer T (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14:191–201CrossRefPubMed
32.
Orme ME, Chaplain MA (1996) A mathematical model of the first steps of tumour-related angiogenesis: capillary sprout formation and secondary branching. IMA J Math Appl Med Biol 13:73–98CrossRefPubMed
33.
Chaplain MA, Anderson AR (1996) Mathematical modelling, simulation and prediction of tumour-induced angiogenesis. Invasion Metastasis 16:222–234PubMed
Metadata
Title
Quantitative Imaging of Morphometric and Metabolic Signatures Reveals Heterogeneity in Drug Response of Three-Dimensional Mammary Tumor Spheroids
Author
V. Krishnan Ramanujan
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 3/2019
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-019-01324-7

Other articles of this Issue 3/2019

Molecular Imaging and Biology 3/2019 Go to the issue

Research Article

Predictive Value of [18F]ML-10 PET/CT in Early Response Evaluation of Combination Radiotherapy with Cetuximab on Nasopharyngeal Carcinoma

Research Article

Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer

Editorial

Commemorating Britton Chance

Research Article

SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb

Research Article

Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT

Brief Article

Sparse Detector Configuration in SiPM Digital Photon Counting PET: a Feasibility Study